

U.S.S.N. 09/706,045
Filed: November 3, 2000
AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

Please enter the following amendment.

Claims 1-22 (canceled).

23. (Currently Amended) A method of delivering a drug to a patient in need thereof, comprising
- administering a therapeutically or prophylactically effective amount of the drug in a formulation comprising a porous matrix which comprises a wetting agent and microparticles of the drug, wherein the microparticles have a mean diameter between about 0.1 and 5 μm and a total surface area greater than about 0.5 m^2/mL , and wherein the porous matrix has a TAP density less than or equal to 1.0 g/mL ~~and/or~~ or has a total surface area of greater than or equal to 0.2 m^2/g and is in the form of a dry powder, and
- wherein the porous matrix is made by a process comprising
- dissolving the drug in a volatile solvent to form a drug solution,
- combining at least one volatile salt with the drug solution to form an emulsion, suspension, or second solution,
- incorporating at least one wetting agent into the emulsion, suspension, or second solution,
- and
- removing the volatile solvent and volatile salt from the emulsion, suspension, or second solution to yield the porous matrix.

U.S.S.N. 09/706,045

Filed: November 3, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

24. (Currently Amended) The method of claim 23 wherein the formulation is ~~suitable for administration~~ administered by a route selected from the group consisting of parenteral, mucosal, oral, and topical administration.

25. (Previously Presented) The method of claim 24 wherein the parenteral route is selected from the group consisting of intravenous, intraarterial, intracardiac, intrathecal, intraosseous, intraarticular, intrasynovial, intracutaneous, subcutaneous, and intramuscular administration.

26. (Original) The method of claim 24 wherein the mucosal route is selected from the group consisting of pulmonary, buccal, sublingual, intranasal, rectal, and vaginal administration.

27. (Currently Amended) The method of claim 23 wherein the formulation is ~~suitable for~~ administered by intraocular or conjunctival administration.

28. (Currently Amended) The method of claim 23 wherein the formulation is ~~suitable for~~ administered by intracranial, intralesional, or intratumoral administration.

29. (Previously Amended Once) The method of claim 23 wherein the formulation is suspended in an aqueous solution suitable for parenteral administration.

30. (Original) The method of claim 23 wherein the formulation is in a tablet or capsule suitable for oral administration.

31. (Original) The method of claim 23 wherein the formulation is in a suppository suitable for vaginal or rectal administration.

U.S.S.N. 09/706,045

Filed: November 3, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

32. (Currently Amended) The method of claim 23 wherein the formulation is ~~suitable~~
for administered by pulmonary administration.

33. (Previously Presented) The method of claim 23 wherein the dry powder form of the porous matrix has a TAP density less than or equal to 1.0 g/mL.

34. (Previously Presented) The method of claim 23 wherein the dry powder form of the porous matrix has a total surface area of greater than or equal to 0.2 m²/g.

35. (Previously Presented) The method of claim 23 wherein the mean diameter of the microparticles is between about 0.5 and 5 μ m.

36. (Previously Presented) The method of claim 23 wherein the drug is a low aqueous solubility drug.

37. (Previously Presented) The method of claim 36 wherein the drug is selected from the group consisting of albuterol, adapalene, doxazosin mesylate, mometasone furoate, ursodiol, amphotericin, enalapril maleate, felodipine, nefazodone hydrochloride, valrubicin, albendazole, conjugated estrogens, medroxyprogesterone acetate, nicardipine hydrochloride, zolpidem tartrate, amlodipine besylate, ethinyl estradiol, omeprazole, rubitecan, amlodipine besylate/benazepril hydrochloride, etodolac, paroxetine hydrochloride, paclitaxel, atovaquone, felodipine, podofilox, paricalcitol, betamethasone dipropionate, fentanyl, pramipexole dihydrochloride, Vitamin D₃, finasteride, quetiapine fumarate, alprostadil, candesartan, cilexetil, fluconazole, ritonavir, busulfan, carbamazepine, flumazenil, risperidone, carbamazepine, carbidopa/levodopa, ganciclovir, saquinavir, amprenavir, carboplatin, glyburide, sertraline hydrochloride,

U.S.S.N. 09/706,045

Filed: November 3, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

rofecoxib, carvedilol, halobetasol propionate, sildenafil citrate, celecoxib, chlorthalidone, imiquimod, simvastatin, citalopram, ciprofloxacin, irinotecan hydrochloride, sparfloxacin, efavirenz, cisapride monohydrate, lansoprazole, tamsulosin hydrochloride, mofafinil, azithromycin, clarithromycin, letrozole, terbinafine hydrochloride, rosiglitazone maleate, diclofenac sodium, lomefloxacin hydrochloride, tirofiban hydrochloride, telmisartan, diazepam, loratadine, toremifene citrate, thalidomide, dinoprostone, mefloquine hydrochloride, trandolapril, docetaxel, mitoxantrone hydrochloride, tretinoin, etodolac, triamcinolone acetate, estradiol, ursodiol, nelfinavir mesylate, indinavir, beclomethasone dipropionate, oxaprozin, flutamide, famotidine, nifedipine, prednisone, cefuroxime, lorazepam, digoxin, lovastatin, griseofulvin, naproxen, ibuprofen, isotretinoin, tamoxifen citrate, nimodipine, amiodarone, and alprazolam.

38. (Previously Presented) The method of claim 23 wherein the drug is a water soluble drug.

39. (Previously Presented) The method of claim 38 wherein the drug is selected from the group consisting of ceftriaxone, ketoconazole, ceftazidime, oxaprozin, valacyclovir, urofollitropin, famciclovir, flutamide, enalapril, mefformin, itraconazole, buspirone, gabapentin, fosinopril, tramadol, acarbose, lorazepam, follitropin, glipizide, omeprazole, fluoxetine, lisinopril, levofloxacin, zafirlukast, interferon, growth hormone, interleukin, erythropoietin, granulocyte stimulating factor, nizatidine, bupropion, perindopril, erbumine, adenosine, alendronate, alprostadil, benazepril, betaxolol, bleomycin sulfate, dexfenfluramine, diltiazem, fentanyl, flecainid, gemcitabine, glatiramer acetate, granisetron, lamivudine, mangafodipir trisodium,

U.S.S.N. 09/706,045

Filed: November 3, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

mesalamine, metoprolol fumarate, metronidazole, miglitol, moexipril, monteleukast, octreotide acetate, olopatadine, paricalcitol, somatropin, sumatriptan succinate, tacrine, verapamil, nabumetone, trovafloxacin, dolasetron, zidovudine, finasteride, tobramycin, isradipine, tolcapone, enoxaparin, fluconazole, lansoprazole, terbinafine, pamidronate, didanosine, diclofenac, cisapride, venlafaxine, troglitazone, fluvastatin, losartan, imiglucerase, donepezil, olanzapine, valsartan, fexofenadine, calcitonin, and ipratropium.